PVI
CBAY

Pura Vida Investments’s Cymabay Therapeutics CBAY Stock Holding History

Pura Vida Investments’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-354,000
Closed -$524K – 145
2020
Q1 		$524K Buy
354,000
+27,000
+8% +$45.3K 0.06% 88
2019
Q4 		$641K Buy
327,000
+27,000
+9% +$101K 0.06% 97
2019
Q3 		$1.54M Buy
+300,000
New +$1.82M 0.26% 72

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pura Vida Investments's CBAY Position: Q2 2016 in Review

Pura Vida Investments sold out of Cymabay Therapeutics (CBAY) in Q2 2016, closing a stake of 56,000 shares — an estimated $76K sold.

Pura Vida Investments first reported a position in CBAY in Q2 2015 and held it in 4 quarters. The position peaked at $602K in Q2 2015. 26 funds tracked by Wall St. Rank hold CBAY as of Q2 2016.

  • Pura Vida Investments reported no remaining Cymabay Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Pura Vida Investments sold 56,000 Cymabay Therapeutics shares in Q2 2016, an estimated $76K.
  • Pura Vida Investments first reported a position in Cymabay Therapeutics in Q2 2015 and held it in 4 quarters.
  • Pura Vida Investments's Cymabay Therapeutics position peaked at $602K in Q2 2015.
  • 26 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2016.

Based on Pura Vida Investments's 13F filing for Q2 2016, filed 15 Aug 2016.